Although this patient was ultimately determined to have progression by RECIST v1.1 and removed from treatment, immunohistochemistry staining from the posttreatment right kidney metastasis biopsy revealed a moderate-to-high number and density of CD45+ and CD3+ tumor-infiltrating lymphocytes (TILs) (Fig. 3). The gene discussed is PTPRC; the disease is neoplasm.